News

The appeals court also reversed a sanctions determination against Medtronic, finding that it was legally incorrect and could not be sustained. The appeals court affirmed an award of

EZN-2968 is the first clinical product candidate to target the HIF-1 transcription factor. HIF-1 regulates expression of many key genes important in cancer biology. Jeffrey Buchalter, Enzon’s Chairman

Among other things, the complete response letter includes certain assigned works for the company. FDA has said that the company need to conduct an additional clinical efficacy trial

Frank Baldino, Chairman and CEO, Cephalon, said:” We are proud to be able to bring Nuvigil to physicians and patients and to increase access to the medication through

The proposals include: The Advanced Medical Technology Association said it would take initiatives to reduce medical errors, for example by improving the design of medical devices. America’s Health

However, this efficacy was not accompanied by the severe toxicities reported in patients treated with cetuximab. The results further conclude that this trial challenges the adopted tenet that

The new operations provide Kendle’ customers (mainly global biopharmaceutical players) access to additional patient populations while strengthening the company’s position as a global clinical development partner. Candace Kendle,

The North America-based, randomized, multi-center, double-blind, placebo-controlled, dose-range-finding, parallel group phase II(b) study was designed to assess the safety, efficacy, and dose response of linaclotide in patients with

These results were obtained from subset analysis of the Phase 3 evaluation of Natalizumab as Continuous Therapy (ENACT-2) and efficacy of Natalizumab in Crohn’s Disease Response and Remission